<DOC>
	<DOCNO>NCT02543892</DOCNO>
	<brief_summary>This study determine PATH-wSP , vaccine germ cause pneumonia , safe induces immune response adult toddler . The study vaccine compare placebo . First adults receive 2 injection low dose vaccine placebo , 28 day apart . If low dose safe , high dose test . Once safety establish adult lower high dose test toddler , start low dose .</brief_summary>
	<brief_title>A Study Vaccine Pneumonia Adults Toddlers Kenya</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult 18 40 year old , toddlers 12 19 month old . Must provide voluntary written/thumbprinted informed consent Must comply study requirement procedure . Must identifiable place residence allow home visit , consistent mean telephone contact Must resident study area plan travel outside study area study Must willing take herbal local traditional medication within 28 day randomization course study Adult female subject must negative serum pregnancy test screen urine pregnancy test prior vaccination Toddlers must bear fullterm , midupper arm circumference &gt; 11.5 cm time enrollment . Toddlers must complete Kenyan infant EPI schedule 9 month include 1 birth dose BCG , 3 dos DTwPHibHep , 3 dos OPV ( birth dose require ) , 3 dos PCV , 1 dose measles vaccine Use investigational nonregistered drug within 90 day enrollment Use potentially hepatotoxic drug Receipt license vaccine within 14 day administration study vaccine . Chronic , clinically significant pulmonary , cardiovascular , hepatobiliary , gastrointestinal , renal , neurological , hematological functional abnormality major congenital defect illness require medical therapy , base medical history clinical assessment History anaphylactic shock History serious reaction prior vaccination know hypersensitivity component study vaccine History immunosuppression immunodeficiency , inclusive human immunodeficiency virus ( HIV ) infection medical history ( include enrol toddler 's mother ) HIV test screen Evidence active hepatitis infection ( B C ) serologic test screen . Any screening laboratory test ( chemistry hematology ) vital sign measurement toxicity grade ≥ 1 Acute illness ( moderate severe ) and/or fever ( axillary temperature ≥ 37.5°C ) Positive test malaria ( blood film ) screening remain positive post treatment retested prior vaccination Disorders require chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug within past 6 month prior administration study vaccine . Administration immunoglobulins and/or blood product within 6 month precede enrollment study Known disturbance coagulation blood disorder ( e.g. , thalassemia , sickle cell disease , thrombocytopenia , disorder lymphocyte , severe anemia birth ) adult subject self/firstdegree relative toddler subject ; receipt anticoagulant past three week ( aspirin need nonsteroidal antiinflammatory drug acceptable ) History meningitis , seizures neurological disorder ( participant ) major psychiatric disorder ( adult ) Any medical social condition opinion investigator interfere study objective pose risk study subject An employee ( firstdegree relative employee ) Sponsor , CRO , investigator site personnel Female adult subject pregnant breastfeeding Adults recent history ( within past year ) alcohol substance abuse . Toddlers already receive pentavalent booster ( follow primary series ) . Toddlers family history suspect primary immunodeficiency firstdegree relative . Toddlers sibling die likely sudden infant death syndrome ( SIDS ) die suddenly without apparent cause precede illness first year life . Toddlers evidence clinically significant congenital abnormality judge PI . Toddlers evidence fetal alcohol syndrome maternal history alcohol abuse pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vaccine</keyword>
</DOC>